Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Leveraging the molecular biology of gastrointestinal cancers for optimal benefit from immunotherapeutic approaches

Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy

Date

03 Dec 2023

Session

Leveraging the molecular biology of gastrointestinal cancers for optimal benefit from immunotherapeutic approaches

Topics

Targeted Therapy;  Immunotherapy

Tumour Site

Hepatobiliary Cancers

Presenters

Stephen Chan

Authors

S.L. Chan

Author affiliations

  • Clinical Oncology Department, The Chinese University of Hong Kong - Sino Building, Sha Tin/HK

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.